Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

159.25USD
9:00pm BST
Change (% chg)

$1.00 (+0.63%)
Prev Close
$158.25
Open
$158.81
Day's High
$159.85
Day's Low
$158.53
Volume
534,204
Avg. Vol
774,143
52-wk High
$197.00
52-wk Low
$114.27

Latest Key Developments (Source: Significant Developments)

Allergan Reports Q2 Loss Per Share of $5.37
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Allergan Plc ::ALLERGAN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 GAAP LOSS PER SHARE $5.37.Q2 EARNINGS PER SHARE ESTIMATE $4.34 -- REFINITIV IBES DATA.RAISES GUIDANCE FOR FULL-YEAR 2019 NET REVENUE.REAFFIRMS GUIDANCE FOR FULL-YEAR 2019 PERFORMANCE NET INCOME PER SHARE.Q2 REVENUE FELL 0.8 PERCENT TO $4.09 BILLION.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.38.RESTASIS NET REVENUE IN Q2 2019 WERE $310.9 MILLION, A DECREASE OF 2.3 PERCENT.SEES 2019 TOTAL NET REVENUES $15.425 BILLION TO $15.625 BILLION.SEES 2019 LOSS PER SHARE OF MORE THAN $12.03.SEES 2019 NON-GAAP TOTAL NET REVENUE OF $15.4 BILLION - $15.6 BILLION.DUE TO PROPOSED ACQUISITION OF ALLERGAN BY ABBVIE, ALLERGAN IS NOT HOSTING A CONFERENCE CALL TO DISCUSS ITS Q2 RESULTS.FY2019 EARNINGS PER SHARE VIEW $16.72, REVENUE VIEW $15.34 BILLION -- REFINITIV IBES DATA.Q2 2019 GAAP REVENUES AND EXPENSES IMPACTED BY VOLUNTARY GLOBAL RECALL OF BIOCELL TEXTURED BREAST IMPLANTS.RECORDED TOTAL PRE-TAX IMPAIRMENT CHARGES OF $1.65 BILLION FOR QUARTER.TOTAL PRE-TAX IMPAIRMENT CHARGES FOR QUARTER INCLUDES GOODWILL IMPAIRMENT OF $1.09 BILLION IN GENERAL MEDICINE REPORTING UNIT.  Full Article

Allergan Reports Second Quarter 2019 Financial Results
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Allergan Plc ::ALLERGAN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 GAAP LOSS PER SHARE $5.37.Q2 EARNINGS PER SHARE ESTIMATE $4.34 -- REFINITIV IBES DATA.RAISES GUIDANCE FOR FULL-YEAR 2019 NET REVENUE.REAFFIRMS GUIDANCE FOR FULL-YEAR 2019 PERFORMANCE NET INCOME PER SHARE.Q2 REVENUE FELL 0.8 PERCENT TO $4.09 BILLION.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.38.RESTASIS NET REVENUE IN Q2 2019 WERE $310.9 MILLION, A DECREASE OF 2.3 PERCENT.SEES 2019 TOTAL NET REVENUES $15.425 BILLION TO $15.625 BILLION.SEES 2019 LOSS PER SHARE OF MORE THAN $12.03.SEES NON-GAAP TOTAL NET REVENUE OF $15.4 BILLION - $15.6 BILLION.DUE TO PROPOSED ACQUISITION OF ALLERGAN BY ABBVIE, ALLERGAN IS NOT HOSTING A CONFERENCE CALL TO DISCUSS ITS Q2 RESULTS.2019 GAAP REVENUES AND EXPENSES IMPACTED BY VOLUNTARY GLOBAL RECALL OF BIOCELL TEXTURED BREAST IMPLANTS.FY2019 EARNINGS PER SHARE VIEW $16.72, REVENUE VIEW $15.34 BILLION -- REFINITIV IBES DATA.  Full Article

Allergan And Editas Medicine Initiate The Brilliance Phase 1/2 Clinical Trial Of Agn-151587 For The Treatment Of Lca10
Thursday, 25 Jul 2019 

July 25 (Reuters) - Editas Medicine Inc ::ALLERGAN AND EDITAS MEDICINE INITIATE THE BRILLIANCE PHASE 1/2 CLINICAL TRIAL OF AGN-151587 (EDIT-101) FOR THE TREATMENT OF LCA10.EDITAS MEDICINE INC - EXPECT FIRST PATIENT DOSING IN SECOND HALF OF 2019.EDITAS MEDICINE INC - BRILLIANCE PHASE 1/2 CLINICAL TRIAL OF AGN-151587 (EDIT-101) IS OPEN FOR PATIENT ENROLLMENT.EDITAS MEDICINE INC - BRILLIANCE CLINICAL TRIAL IS A PHASE 1/2 STUDY TO EVALUATE AGN-151587 FOR TREATMENT OF LCA10.  Full Article

Elliott management advocated for an Allergan split prior to sale - Bloomberg Reporter Tweet
Wednesday, 26 Jun 2019 

June 26 (Reuters) - :ELLIOTT HAD BUILT STAKE IN ALLERGAN WAS ADVOCATING FOR BREAK UP OF CO PRIOR TO IT ANNOUNCING PLANS TO BE ACQUIRED BY ABBVIE - BLOOMBERG REPORTER TWEET.  Full Article

AbbVie Believes It Is Unlikely There Will Be A Botox Biosimilar For A Long Time - Conf. Call
Tuesday, 25 Jun 2019 

June 25 (Reuters) - AbbVie Inc ::ABBVIE INC EXECUTIVE SAYS ASSETS OF THE QUALITY OF ALLERGAN ARE NOT ALWAYS AVAILABLE AND NOT CERTAINLY AT THIS VALUE: CONF. CALL.ABBVIE CEO SAYS BELIEVES IT IS HIGHLY UNLIKELY THERE WILL BE A BOTOX BIOSIMILAR FOR A LONG TIME.ABBVIE CEO SAYS FEELS COMFORTABLE WITH RISK RELATED TO ALLERGAN'S OPIOID EXPOSURE.ABBVIE CEO SAYS ALLERGAN BREAKUP FEE IS 1% FOR ALLERGAN, 2% FOR ABBVIE : CONF. CALL.ABBVIE EXECUTIVE SAYS NOT BUILDING IN A LARGE CONTRIBUTION FROM ALLERGAN'S PIPELINE INTO ITS PROJECTIONS.  Full Article

Abbvie To Acquire Allergan For $63 Bln
Tuesday, 25 Jun 2019 

June 25 (Reuters) - AbbVie Inc ::ABBVIE TO ACQUIRE ALLERGAN IN TRANSFORMATIVE MOVE FOR BOTH COMPANIES.TRANSACTION EQUITY VALUE OF APPROXIMATELY $63 BILLION.ALLERGAN SHAREHOLDERS WILL RECEIVE 0.8660 ABBVIE SHARES AND $120.30 IN CASH FOR EACH ALLERGAN SHARE, FOR A TOTAL CONSIDERATION OF $188.24 PER ALLERGAN SHARE.UPON COMPLETION OF TRANSACTION, ABBVIE WILL CONTINUE TO BE INCORPORATED IN DELAWARE AS ABBVIE INC.DEAL IS EXPECTED TO BE 10% ACCRETIVE TO ADJUSTED EARNINGS PER SHARE OVER FIRST FULL YEAR FOLLOWING CLOSE OF TRANSACTION.ABBVIE WILL CONTINUE TO BE LED BY RICHARD A. GONZALEZ AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER.EXPECTED TO GENERATE SIGNIFICANT ANNUAL OPERATING CASH FLOW, WHICH WILL SUPPORT A DEBT REDUCTION TARGET OF $15 TO $18 BILLION BEFORE END OF 2021.ABBVIE ANTICIPATES THAT ACQUISITION WILL PROVIDE ANNUAL PRE-TAX SYNERGIES AND OTHER COST REDUCTIONS OF AT LEAST $2 BILLION IN YEAR THREE.ABBVIE WILL CONTINUE TO BE INCORPORATED IN DELAWARE AS ABBVIE INC. AND HAVE ITS PRINCIPAL EXECUTIVE OFFICES IN NORTH CHICAGO, ILL.2 MEMBERS OF ALLERGAN'S BOARD, INCLUDING CHAIRMAN AND CHIEF EXECUTIVE OFFICER, BRENT SAUNDERS, WILL JOIN ABBVIE'S BOARD UPON CLOSE OF DEAL.COMBINED CO WILL PRODUCE ROBUST CASH FLOW TO SUPPORT CONTINUED DIVIDEND GROWTH, FURTHER INVESTMENT IN PIPELINE AND REDUCTION OF DEBT LEVELS.AFTER DEAL CLOSE, CO'S SHAREHOLDERS TO OWN ABOUT 83% OF CO AND ALLERGAN SHAREHOLDERS WILL OWN ABOUT 17% OF ABBVIE.  Full Article

Abbvie Nears Deal To Buy Allergan For More Than $60 Bln - WSJ
Tuesday, 25 Jun 2019 

June 25 (Reuters) - :ABBVIE NEARS DEAL TO BUY ALLERGAN FOR MORE THAN $60 BILLION - WSJ.ABBVIE'S ALLERGAN TAKEOVER, WORTH $188 A SHARE IN CASH AND STOCK, IS EXPECTED TO BE ANNOUNCED LATER TUESDAY - WSJ, CITING SOURCES.  Full Article

Allergan Receives FDA Clearance For Cooltone Device
Monday, 24 Jun 2019 

June 24 (Reuters) - Allergan plc ::ALLERGAN RECEIVES FDA CLEARANCE FOR COOLTONE™ DEVICE.ALLERGAN PLC - ALLERGAN IS NOW TAKING ORDERS FOR COOLTONE DEVICE, AND FIRST UNITS WILL SHIP EARLY IN Q4 OF THIS YEAR..ALLERGAN - COOLTONE DEVICE GOT FDA CLEARANCE FOR IMPROVEMENT OF ABDOMINAL TONE, STRENGTHENING OF ABDOMINAL MUSCLES, AND DEVELOPMENT FOR FIRMER ABDOMEN.  Full Article

Ironwood And Allergan Report Positive Topline Data From Phase Iiib Trial Of Linzess
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Allergan plc ::IRONWOOD AND ALLERGAN REPORT POSITIVE TOPLINE DATA FROM PHASE IIIB TRIAL OF LINZESS® (LINACLOTIDE) IN ADULTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C).ALLERGAN PLC - PHASE IIIB STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE.ALLERGAN PLC - PHASE IIIB STUDY DEMONSTRATED LINACLOTIDE IMPROVED OVERALL ABDOMINAL SYMPTOMS OF BLOATING, PAIN AND DISCOMFORT IN ADULTS WITH IBS-C.ALLERGAN PLC - LINACLOTIDE WAS WELL-TOLERATED IN THIS PHASE IIIB STUDY, WITH MOST COMMONLY REPORTED ADVERSE EVENT BEING DIARRHEA.  Full Article

FDA Approves Amgen And Allergan's KANJINTI
Friday, 14 Jun 2019 

June 13 (Reuters) - Allergan plc ::FDA APPROVES AMGEN AND ALLERGAN'S KANJINTI™ (TRASTUZUMAB-ANNS), A BIOSIMILAR TO HERCEPTIN® (TRASTUZUMAB).ALLERGAN PLC - U.S. FDA HAS APPROVED KANJINTI™ (TRASTUZUMAB-ANNS) FOR ALL APPROVED INDICATIONS OF REFERENCE PRODUCT, HERCEPTIN(®).  Full Article

UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr

Aug 16 AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.